144 related articles for article (PubMed ID: 36918846)
1. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study).
Schöttle D; Janetzky W; Therrien F; Wiedemann K
BMC Psychiatry; 2023 Mar; 23(1):162. PubMed ID: 36918846
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.
Schöttle D; Clerzius G; Janetzky W; Oluboka O; Roy MA; Therrien F; Wiedemann K
Eur Psychiatry; 2022 Jul; 65(1):e42. PubMed ID: 35855645
[TBL] [Abstract][Full Text] [Related]
4. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
[TBL] [Abstract][Full Text] [Related]
5. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
[TBL] [Abstract][Full Text] [Related]
6. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
[TBL] [Abstract][Full Text] [Related]
7. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
[TBL] [Abstract][Full Text] [Related]
8. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
9. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
11. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
13. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
15. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
Margolese HC; Boucher M; Therrien F; Clerzius G
BMC Psychiatry; 2022 Dec; 22(1):773. PubMed ID: 36482352
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies.
Madera JJ; Such P; Zhao C; Baker RA
Neuropsychiatr Dis Treat; 2019; 15():1593-1604. PubMed ID: 31354275
[No Abstract] [Full Text] [Related]
17. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.
Olivares JM; Fagiolini A
Front Psychiatry; 2022; 13():877867. PubMed ID: 35573364
[TBL] [Abstract][Full Text] [Related]
19. The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2020 Feb; 20(1):77. PubMed ID: 32087718
[TBL] [Abstract][Full Text] [Related]
20. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]